Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

by B2i | Oct 31, 2023 | Press Releases

ROCKVILLE, Md., Oct. 31, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it...

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

by B2i | Oct 10, 2023 | Press Releases

ROCKVILLE, Md., Oct. 10, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

by B2i | Sep 25, 2023 | Press Releases

Company remains on track to initiate the clinical trial in Q4 of 2023 ROCKVILLE, Md., Sept. 25, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of...

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men’s Health Fair

by B2i | Sep 13, 2023 | Press Releases

ROCKVILLE, Md., Sept. 13, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

by B2i | Sep 11, 2023 | Press Releases

ROCKVILLE, Md., Sept. 11, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharma’s Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

by B2i | Aug 29, 2023 | Press Releases

ROCKVILLE, Md., Aug. 29, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...